These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 7789291)

  • 1. Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
    Rains CP; Bryson HM; Peters DH
    Drugs; 1995 Apr; 49(4):577-617. PubMed ID: 7789291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity, pharmacokinetics, therapeutic indications and adverse reactions of ceftazidime.
    Gentry LO
    Pharmacotherapy; 1985; 5(5):254-67. PubMed ID: 3906585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Brogden RN
    Drugs; 1985 Feb; 29(2):105-61. PubMed ID: 3884319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Barradell LB; Bryson HM
    Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftazidime for respiratory infections.
    Choi SH; Koh Y
    Expert Opin Pharmacother; 2012 Oct; 13(14):2097-109. PubMed ID: 22943280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
    Sharma R; Park TE; Moy S
    Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multicenter clinical study and pharmacokinetics of ceftazidime in children and newborn infants].
    Bégué P; Michel B; Chasalette JP; Allouche G; Quinet B
    Pathol Biol (Paris); 1986 May; 34(5):525-9. PubMed ID: 3534737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefpirome. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy in the treatment of severe nosocomial infections and febrile neutropenia.
    Wiseman LR; Lamb HM
    Drugs; 1997 Jul; 54(1):117-40. PubMed ID: 9211085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experiences with ceftazidime in the therapy of neonatal infections].
    de Louvois J
    Infection; 1987; 15 Suppl 4():S209-13. PubMed ID: 3312037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International comparative study of cefepime and ceftazidime in the treatment of serious bacterial infections.
    Hoepelman AI; Kieft H; Aoun M; Kosmidis J; Strand T; Verhoef J; Gillespie SH; Riddell J; Varghese G; Meunier F
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():175-86. PubMed ID: 8150761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of ceftazidime in severe infections in children. Review of the literature].
    Bégué P; Quinet B
    Presse Med; 1988 Oct; 17(37):1944-7. PubMed ID: 2973592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
    Chapman TM; Perry CM
    Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia.
    Mustafa MM; Carlson L; Tkaczewski I; McCracken GH; Buchanan GR
    Pediatr Infect Dis J; 2001 Mar; 20(3):362-9. PubMed ID: 11303851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of ceftazidime. Treatment of serious infection due to multiresistant Pseudomonas and other gram-negative bacteria.
    Scully BE; Neu HC
    Arch Intern Med; 1984 Jan; 144(1):57-62. PubMed ID: 6419690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of ceftazidime pharmacokinetic indices with therapeutic outcome in patients with cystic fibrosis.
    Munzenberger PJ; Hsu JM; Holliday SJ
    Pediatr Infect Dis J; 1993 Dec; 12(12):997-1001. PubMed ID: 8108228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of cefepime versus ceftazidime as empiric therapy of febrile episodes in neutropenic patients.
    Wang FD; Liu CY; Hsu HC; Gau JP; Chau WK; Haung ML; Ho CH
    Chemotherapy; 1999; 45(5):370-9. PubMed ID: 10473925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ceftazidime in the treatment of 80 infectious episodes in compromised children.
    Viscoli C; Gargani G; Facco F; Mantero E; Tuo P; Giacchino R; Campelli A; Nantron M; Perlino G
    Int J Clin Pharmacol Ther Toxicol; 1985 Nov; 23(11):629-34. PubMed ID: 3908333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
    Shirley M
    Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.